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RESEARCH LETTER
Cost-Effectiveness of Cardiovascular, Obesity, 
and Diabetes Mellitus Drugs: Comparative 
Analysis of the United States and England
Avi Cherla, MSc; Matthew Renwick, MD, MSc; Giulio Stefanini , MD, PhD; David R. Holmes Jr , MD;  
Elias Mossialos , MD, PhD
Multiple drugs for cardiovascular disease, obe-sity, and diabetes mellitus have been recently approved; however, it can be challenging to 
determine whether these drugs represent worthwhile 
improvements in cost-effectiveness over standard 
treatment regimens. England is one of several high-in-
come countries that integrates evidence-based value 
assessments within pricing decisions and consistently 
has one of the lowest pharmaceutical expenditure 
per capita.1 In England, the cost-effectiveness of new 
drugs is evaluated by the National Institute for Health 
and Care Excellence (NICE), a national public agency, 
while the Institute for Clinical and Economic Review 
(ICER) is an independent nongovernmental organiza-
tion providing recommendations to private insurers for 
coverage decisions in the United States. We compared 
ICER’s assessments of cardiovascular, obesity, and di-
abetes mellitus drugs with those similarly assessed by 
NICE in order to determine whether there are differ-
ences in how these organizations, from 2 of the largest 
pharmaceutical markets, evaluate cost-effectiveness 
and make coverage recommendations.
We analyzed assessment reports for drugs indi-
cated for cardiovascular disease, obesity, and diabetes 
mellitus until April 2020 since ICER began publishing 
assessments in 2006. Drugs with assessments for 
cost-effectiveness measured using the incremental 
cost-effectiveness ratio (cost per quality-adjusted life-
year [QALY]) from ICER were compared with public 
appraisal documents from NICE. Additional charac-
teristics including comparator treatment, coverage 
recommendation, price, and the methodology of the 
economic evaluation (perspective, model, time hori-
zon, outcome, and discount rate) were also compared. 
The authors declare that all supporting data are avail-
able within the article.
Ten drugs were similarly assessed for cost-effec-
tiveness measured in cost/QALY indicated for cardio-
vascular disease, obesity, or diabetes mellitus (Table). 
In the United States, 5 drugs were within ICER’s ac-
ceptable range for cost-effectiveness ($100–$150K/
QALY) and below the threshold (sacubitril/valsartan, 
ranibizumab, pegaptanib, dronedarone, and naltrex-
one/bupropion), while 5 drugs were not recommended 
for coverage from private insurers at their current list or 
net price unless prices were discounted.
In England, 8 drugs were recommended for public 
coverage in England’s National Health Service (NHS), 
while 2 were not approved (pegaptanib and naltrexone/
bupropion). Confidential discounts were negotiated be-
tween manufacturers and the NHS to improve the clini-
cal and cost-effectiveness of drugs for public coverage 
subject to price reductions. Five of the 8 drugs approved 
by NICE for coverage in England’s NHS were subject to 
price discounts to improve cost-effectiveness as they 
were evaluated as cost-ineffective at their list price.
ICER and NICE were in concordance for 3 drugs 
(sacubitril/valsartan, ranibizumab, and dronedarone), 
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which were approved in both the United States and 
England and evaluated as cost-effective. In contrast, 
both agencies had discordant recommendations for 
7 drugs. For 5 drugs (dabigatran, alirocumab, evolo-
cumab, patisiran, and inotersen), the discordance was 
attributed to the higher price of drugs in the United 
States, which resulted in higher cost/QALY evalua-
tions. For example, both amyloidosis drugs were well 
above NICE’s commonly accepted cost-effective-
ness threshold but were accepted for coverage with 
price discounts because of their efficacy. Similarly, 
ICER concluded that both were clinically effective, 
but they exceeded the cost-effectiveness threshold 
from ICER because of their prices. For the remaining 
2 drugs, both agencies were in discordance regard-
ing the cost-effectiveness evaluations for pegaptanib 
(with NICE having a significantly higher estimate for 
cost-effectiveness) and the long-term clinical effec-
tiveness of naltrexone/bupropion (with NICE hesitant 
when evaluating cost-effectiveness because of the 
long-term uncertainty of benefit).
Our analysis shows that only 5 cardiovascular, obe-
sity, and diabetes mellitus drugs assessed by ICER 
and 8 drugs from NICE were considered cost-effective 
(based on the negotiated price discounts achieved by 
NICE), indicating that some newer drugs do not repre-
sent strong value for the money. Despite similar meth-
odologies and results for evaluating cost-effectiveness, 
the high discordance for recommendations to payers on 
whether to include a new cardiovascular, obesity, or dia-
betes mellitus drug in their formularies is mostly a result 
of the United States’ higher drug prices and thresholds 
for value. In England, NICE negotiated price discounts on 
multiple drugs to a point where they could be considered 
cost-effective, whereas these same drugs assessed by 
ICER, which has no bargaining role, were valued using a 
higher list or net price that firmly positioned these drugs 
as cost-ineffective. Comparatively, when ICER deter-
mined that a drug was cost-effective using its higher 
value threshold of $100K to $150K/QALY, NICE was 
often unable to negotiate a cost-effective price below 
their comparatively low threshold of £20K to £30K/QALY.
Our investigation was limited to publicly avail-
able data. Stratifying cost-effectiveness into clinical 
modeling for efficacy and drug prices was not possi-
ble as the former was largely redacted from NICE ap-
praisals, while drug prices were not uniformly reported 
among ICER and NICE assessments. The cost/QALY 
estimate from NICE’s appraisal documents was inclu-
sive of confidential price discounts, whereas ICER’s 
cost/QALY was based on an assumed net or list price. 
Therefore, our study will likely overestimate the differ-
ence in cost-effectiveness.
ICER’s decisions are increasingly referenced 
by private insurers for formulary decisions2; how-
ever, there is an absence of a public government 
agency in the United States, which evaluates the 
cost-effectiveness of medicines for coverage within 
public insurance programs including Medicare and 
Medicaid. Integrating value-based evidence in for-
mulary listings, such as in England, has significant 
potential to reduce pharmaceutical expenditure in 
the United States by sending price signals to the 
market that cardiovascular, obesity, and diabetes 
mellitus drugs with high prices and marginal im-
provements in effectiveness over current standards 
of care will not be covered by public insurers.
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